Courante Oncology

Executive Summary

Courante Oncology, operating under the brand Harvest Integrated Research Organization (HiRO), is a full-service global Contract Research Organization (CRO) founded in 2020 and headquartered in San Francisco. The company specializes in oncology and digital health, offering integrated clinical trial services that emphasize disciplined execution, data science, and global operational frameworks. HiRO positions itself as an agile partner for biotech sponsors, providing clarity and consistency from study startup through closeout. Despite being a relatively new entrant, the company has established a presence in the competitive CRO market by focusing on niche therapeutic areas and leveraging digital health technologies. Its growth trajectory will depend on its ability to secure partnerships, expand its operational footprint, and differentiate through data-driven service offerings. The company is privately held and has not disclosed funding or valuation details.

Upcoming Catalysts (preview)

• Q3 2026Major Biotech Partnership Announcement60% success
• Q4 2026Geographic Expansion into Asia-Pacific or Europe50% success
• Q2 2026Launch of Proprietary Digital Health Platform or Data Analytics Tool40% success